ALLMedicine™ Squamous Cell Carcinoma Center
Research & Reviews 22,888 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108409
International Journal of Medical Sciences; Chen KJ, Hsieh MH et. al.
May 19th, 2022 - Oral cancer is the eighth greatest generally diagnosed cancer amongst males worldwide and the fourth most generally malignancy amongst Taiwanese males. The pro-inflammatory adipocytokine visfatin promotes tumor growth. Elevated plasma visfatin lev...
https://doi.org/10.1097/MD.0000000000029197 10.1371/journal.pone.0223298 10.7717/peerj.6724
Medicine Kim CH, Cha YK et. al.
May 19th, 2022 - Basaloid squamous cell carcinoma (SCC) is very rare subtype of SCC of the lung and it is important to distinguish basaloid to other subtypes of SCCs, since the prognosis of basaloid subtype is considered poorer than that of other non-basaloid subt...
https://doi.org/10.1097/MD.0000000000029285
Medicine Lin NC, Hsu JT et. al.
May 19th, 2022 - Primary surgical treatment for oral squamous cell carcinoma (OSCC) is reserved for T1 to T4a tumors, but not for T4b tumors, according to the present National Comprehensive Cancer Network clinical practice guidelines. In this retrospective study, ...
https://doi.org/10.1111/odi.14255
Oral Diseases; Ito Y, Abe A et. al.
May 19th, 2022 - To investigate the prognostic impact of preoperative Geriatric Nutritional Risk Index (GNRI) values in older adults undergoing radical surgery for oral squamous cell carcinoma (OSCC). This retrospective study included 61 patients ≥ 65 years old wi...
https://doi.org/10.1186/s12880-022-00804-7 10.3322/caac.21660 10.3322/caac.21338 10.1007/s00268-017-4024-5 10.1186/s13019-019-0883-1 10.1097/CEJ.0000000000000249 10.1016/j.jtho.2015.12.109 10.1200/JCO.2008.17.2361 10.21873/anticanres.14442 10.1016/j.surg.2016.02.034 10.1093/dote/doy083 10.1007/s00330-015-3847-4 10.1007/s00330-009-1331-8 10.1055/s-0043-124433 10.1007/s00330-016-4695-6 10.3389/fonc.2020.602681 10.1148/radiology.219.1.r01ap0361 10.1016/j.crad.2013.06.009 10.1016/j.jcm.2016.02.012 10.2214/AJR.14.12460 10.1245/s10434-021-10467-3 10.1093/ajcp/aqaa021 10.1148/radiol.2393050222 10.1007/s00330-011-2187-2 10.2214/AJR.12.9206 10.4329/wjr.v4.i4.179 10.1016/j.pan.2014.02.005 10.1148/radiol.11101777 10.1016/j.clinimag.2007.08.022 10.1007/s12029-019-00337-3 10.1259/bjr/65897774 10.3748/wjg.v9.i2.219 10.1148/radiology.181.2.1924783 10.1007/s00261-019-01911-w 10.1245/s10434-016-5228-x 10.3348/kjr.2020.0984 10.1007/s00330-015-4172-7 10.1148/radiol.2303030157 10.1016/j.clinimag.2013.08.002
BMC Medical Imaging; Li Y, Su H et. al.
May 18th, 2022 - To investigate the value of contrast-enhanced CT (CECT)-derived imaging features in predicting lymphovascular invasion (LVI) status in esophageal squamous cell carcinoma (ESCC) patients. One hundred and ninety-seven patients with postoperative pat...
Guidelines 36 results
https://doi.org/10.1097/CMR.0000000000000788
Melanoma Research; Cakir OO, Pozzi E et. al.
Nov 30th, 2021 - Penile mucosal melanoma is an aggressive and rare genital malignancy. The aim of the present study was to review the management and outcomes of a homogenous cohort of patients with histologically confirmed penile mucosal melanoma, at a single spec...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495291
Cancer Medicine; Lee LY, Lin CY et. al.
Sep 18th, 2021 - We sought to compare the prognostic impact of tumor differentiation with respect to adverse risk factors (RFs) identified by the National Comprehensive Cancer Network (NCCN) guidelines--including extranodal extension (ENE), positive/close margins,...
https://doi.org/10.1016/j.jacr.2021.02.016
Journal of the American College of Radiology : JACR; , Lakhman Y et. al.
May 8th, 2021 - Vulvar cancer is an uncommon gynecologic tumor and one of several human papillomavirus-associated malignancies. Squamous cell carcinoma is the most prevalent histologic subtype of vulvar cancer, accounting for the majority of cases. Imaging plays ...
https://doi.org/10.1111/ced.14587
Clinical and Experimental Dermatology; Woo WA, Suarez M-Falero B et. al.
Mar 18th, 2021 - Summary of the updated 2020 guidelines for cutaneous squamous cell carcinoma.|2021|Woo WA,Suarez M-Falero B,Keohane SG,|pathology,therapy,pathology,therapy,
https://doi.org/10.1016/j.annonc.2020.07.011
Annals of Oncology : Official Journal of the European Soc... Machiels JP, René Leemans C et. al.
Nov 27th, 2020 - Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2020|Machiels JP,René Leemans C,Golusinski W,Grau C,Licitra L,|diagnosis,epidemiol...
Drugs 44 results see all →
Clinicaltrials.gov 641 results
https://clinicaltrials.gov/ct2/show/NCT04432597
May 13th, 2022 - Background Metastatic HPV associated malignancies (cervical, anal, oropharyngeal cancers, etc.) are often incurable and poorly palliated by standard therapies. HPV-positive (p16+) oropharyngeal cancers are the most common HPV-associated malignancy...
https://clinicaltrials.gov/ct2/show/NCT04428151
May 13th, 2022 - This study is designed to assess the safety and efficacy of lenvatinib in combination with pembrolizumab versus standard of care (SOC) chemotherapy, and to also assess the safety and efficacy of lenvatinib monotherapy in participants with recurren...
https://clinicaltrials.gov/ct2/show/NCT04847466
May 13th, 2022 - Background: Natural killer (NK) cells are an important component of an anti-tumor immune response. PD-L1 CAR-NK (PD-L1 t-haNKs) is an off the shelf, irradiated human, allogeneic, NK cell line that is frozen, shipped, thawed and then infused. PD-L1...
https://clinicaltrials.gov/ct2/show/NCT04989387
May 13th, 2022 - This is an open-label, nonrandomized, multicenter, dose escalation, and dose expansion first-in human (FIH) Phase 1 study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCA00186 when given alone or in com...
https://clinicaltrials.gov/ct2/show/NCT04925700
May 13th, 2022 - Previous work by a number of scientific teams has revealed that the types of bacteria that colonize the mouth differ between health and pre-cancerous or cancerous oral lesions. The purpose of this study is to investigate the extent of these change...
News 996 results
https://www.medscape.com/viewarticle/974234
May 18th, 2022 - Patients receiving treatment with ibrutinib for chronic lymphocytic leukemia (CLL) show significant increases in the risk for bleeding when undergoing Mohs micrographic surgery for skin cancer, indicating the need for temporary treatment interrupt...
https://www.medscape.com/viewarticle/973526
May 6th, 2022 - NEW YORK (Reuters Health) - In patients with multiple actinic keratoses (AKs), Olson grade III and the need for more treatment were identified as markers for increased risk of cutaneous squamous cell carcinoma (cSCC) in a secondary analysis of a r...
https://www.onclive.com/view/pembrolizumab-with-or-without-chemo-has-increased-efficacy-with-increasing-pd-l1-expression-in-hnscc
May 4th, 2022 - Pembrolizumab (Keytruda) with or without chemotherapy resulted in a numerically longer overall survival (OS) benefit vs cetuximab (Erbitux) plus chemotherapy in patients with head and neck squamous cell carcinoma (HNSCC) and a PD-L1 combined posit...
https://www.onclive.com/view/sot101-plus-pembrolizumab-elicits-encouraging-efficacy-in-advanced-solid-tumors
May 2nd, 2022 - The addition of SOT101, an interleukin (IL)-2/IL-15 Rβγ superagonist, to Pembrolizumab (Keytruda) generated a clinical benefit and encouraging safety data in patients with advanced solid tumors, according to data presented at the 2022 AACR Annual ...
https://www.medpagetoday.com/hematologyoncology/othercancers/98467
Apr 29th, 2022 - The National Comprehensive Cancer Network endorsed a second COVID mRNA booster for immunocompromised individuals, bringing the total to five jabs, as three is considered standard for someone who is immunocompromised. In a first-quarter earnings st...
